Molecular Cancer Theraputics: Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma (Ignatius, Vaseva, Houghton Labs)
January 3, 2023
Nicole R. Hensch, Kathryn Bondra, Long Wang, Prethish Sreenivas, Xiang R. Zhao, Paulomi Modi, Angelina V. Vaseva, Peter J. Houghton, Myron S. Ignatius Abstract In fusion-negative rhabdomyosarcoma (FN-RMS), a pediatric malignancy with skeletal muscle characteristics, >90% of high-risk patients have mutations that activate the RAS/MEK signaling pathway. We recently discovered that SNAI2, in addition to [...]